ALSO NOTED: Pfizer demands peer reviews from NEJM; Novartis gets EU nod for diabetes combo;

> Pfizer wants the New England Journal of Medicine to turn over confidential peer reviews of studies involving the painkillers Celebrex and Bextra; those articles have been cited in plaintiffs' lawsuits over the drugs. Report

> Novartis won the nod from European regulators for its diabetes combo treatment Eucreas, which comprises the company's new Galvus treatment and old standby metformin. Report

> President Bush's new FDA budget includes a boost in funding for examination of DTC ads; the catch is that the funding comes from user fees, a method Congress rejected last year. Report

> FTC Commissioner Jon Leibowitz explained his agency's opposition to pay-to-delay deals between brand-name drug makers and generics firms in a Washington Post op-ed piece. Report

> Boston Scientific got the FDA nod for three heart-related products: Confient and Livian, two defibrillators; and Latitude, a computer system that helps doctors monitor patients' hearts between visits. Report

> The FDA has granted priority review to Eli Lilly and Daiichi Sankyo's prasugrel, an anti-clotting drug. Report

> Novartis has established the Novartis Vaccines Institute for Global Health, a nonprofit venture that will take aim at diseases in the developing world. Report

And Finally... The shooting spree at Northern Illinois University has revived a debate over antidepressants and whether they might be linked to violent behavior. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.